Sight Sciences , Inc. (NASDAQ:SGHT) recently saw its Executive Vice President of Research & Development, Manohar K. Raheja, make a significant purchase of the company's common stock. According to a filing with the Securities and Exchange Commission, Raheja acquired 3,376 shares on December 3, 2024, at a price of $3.89 per share. This transaction amounts to a total value of $13,132. Following this purchase, Raheja's total ownership in the company stands at 106,000 shares. InvestingPro data shows the company maintains a strong balance sheet with more cash than debt, though stock price movements remain quite volatile. For deeper insights into insider trading patterns and 8 additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Sight Sciences, Inc. reported a minor year-over-year revenue increase in its third-quarter earnings call despite the results falling short of expectations. The company's third-quarter revenue rose 1% year-over-year to $20.2 million, with surgical glaucoma revenue at $18.6 million. However, it witnessed a sequential decrease of 8% in surgical glaucoma revenue and a decrease in OMNI device utilization due to competition and LCD process uncertainty.
Despite these setbacks, Sight Sciences remains optimistic about growth in the surgical glaucoma and dry eye segments in 2025. The company is contesting the final 2025 Medicare payment rule, which did not grant device-intensive status to OMNI procedures, and is focused on enhancing its sales performance and strategic positioning.
Recent developments include the appointment of Dr. MK Raheja as Executive Vice President of Research and Development to advance their surgical glaucoma pipeline. Furthermore, Sight Sciences has conducted over 200,000 OMNI and 60,000 TearCare procedures, demonstrating the company's ongoing commitment to improving patient care and expanding market access.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.